vTv Therapeutics Inc. (VTVT): Nasdaq/NYSE listing notice — vTv Therapeutics receives Nasdaq delisting notice; appeals, hearing set for Aug 17, 2023

vTv Therapeutics Inc.

Received delisting notice on June 21, 2023 for failure to regain compliance with minimum bid price rule.
Nasdaq to suspend trading June 30, 2023 unless appeal filed; company appealed on June 22, staying suspension.
Hearing before Nasdaq Hearings Panel scheduled for August 17, 2023; company to submit compliance plan.
No assurance of regaining compliance; expedited review questionnaire also submitted.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

vTv Therapeutics Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

June 21, 2023, vTv Therapeutics, Inc. (the “Company”) received a notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq has determined the Company did not regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) by June 20, 2023, the deadline to regain compliance with the Rule pursuant to the notice the Company received from Nasdaq on December 22, 2022 (the “Extension Notice”), and therefore the

View on SEC.gov

Browse all listing & compliance notices →

vTv Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001641489-23-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.